InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,482.87
(
0.09%
)
US TECH 100
19,307.88
(
0.48%
)
Dow Jones
39,164.06
(
0.09%
)
Brent Oil
85.65
(
0.28%
)
Bitcoin
61,459.24
(
-0.25%
)
Post# of 252412
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

dewophile

Send PM Follow Ignore
Followers 44
Posts 4595
Boards Moderated 0
Alias Born 07/19/2006

dewophile

Re: DewDiligence post# 227032

Friday, 11/22/2019 11:06:02 AM

Friday, November 22, 2019 11:06:02 AM

Post# of 252412

If it were up to me, I would bag the EDP-305 NASH program* and move ahead full steam with EDP-297



I was wondering if pruritis was a class effect, but in reading the transcript they mention that the follow on seems to have less plasma and skin exposure while preferentially hitting liver and intestine.

I agree w you on allocation of resources but to put in persepctive the 2b program is 340 patients. assuming about 100K per pt enrolled it's 34M. Not that huge a deal given their resources. If the PBC trial data looks poor then they hopefully will shelve the drug altogether

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up